MONDAY, Dec. 29, 2025 (HealthDay News) — Urinary incontinence (UI) is the involuntary loss of urine. Just having a UI “accident” occasionally may not require attention, but when individuals have UI, ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the treatment of bladder cancer. The PD-1/antibody-drug conjugate pairing ...

Adenocarcinoma of the bladder is rare, originating from glandular cells, and can be primary or secondary, requiring accurate diagnosis for appropriate treatment. Diagnosis involves cystoscopy, biopsy, ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional ...

Squamous cell carcinoma of the bladder is rare, accounting for 2% to 5% of bladder cancers in the U.S., and is linked to chronic bladder irritation. Diagnosis involves cystoscopy, biopsy, and imaging ...

Editor's Note: This is an excerpt from WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here. Bladder cancer hits men especially hard. The ...

An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland. Dr. Heather Chalfin, a urologic ...

Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

Robotic surgery for bladder cancer speeds recovery, reduces pain, and improves quality of life. It also significantly reduces risks such as blood clots and can preserve functions like sexual health.

The FDA has signed off on Johnson & Johnson’s highly anticipated bladder cancer drug Inlexzo, marking an advance in the ability to care for patients who otherwise face bladder removal and limited ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...